Glenmark Life Sciences has signed a Master Supply Agreement (MSA) with a Japanese innovator pharma company. Under the aegis of the Master Supply Agreement, Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the Japanese firm.
As part of this collaboration, product portfolios of various affiliates of the Japanese company may also be added in the future. The API for the finished formulation will be supplied to major regulated markets such as US, Europe and Japan. The estimated commercial value of this project is expected to be around $5million.